Medpace Holdings, Inc.
A contract research organization (CRO), Medpace runs the full span of clinical drug trials — from early safety tests to post-market studies — for small and mid-sized biopharma companies, including medical oversight, monitoring, labs, and regulatory work. Founded in Cincinnati in 1992 by Dr. August Troendle, a former FDA reviewer, it was originally called Medical Research Services; the name Medpace blends "medical" with "pace," reflecting its mission to speed trials along. It also built its own software, ClinTrak, to track studies in real time, and keeps its central labs and a Phase I unit on its own Cincinnati campus.
Granted 356.4K · Sold 2.08M
Sold 1.50M
Granted 128.0K · Sold 77.7K
Granted 151.5K · Sold 142.9K
Granted 29.2K · Sold 9.0K
Granted 41.6K · Bought 2 · Sold 36.1K
Granted 25.4K · Sold 18.4K
Granted 18.8K · Sold 15.0K
Granted 11.8K · Sold 1.7K
Granted 15.3K · Sold 14.6K
Granted 2.0K · Sold 1.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Troendle August J.President & CEO, Director, 10% owner · 75 transactions | +39.2% | 10.65M | 356.4K | — | 2.08M |
| Medpace Investors, LLC10% owner · 32 transactions | -24.1% | 4.73Mas of Mar 2024 | — | — | 1.50M |
| Burwig Susan EExec. VP, Operations · 18 transactions | +249.2% | 70.5K | 128.0K | — | 77.7K |
| Geiger Jesse JPresident · 14 transactions | +631.9% | 46.7K | 151.5K | — | 142.9K |
| Carley Brian TDirector · 16 transactions | +265.8% | 27.8K | 29.2K | — | 9.0K |
| Ewald Stephen PGeneral Counsel & Corp. Secy. · 10 transactions | +37% | 20.3K | 41.6K | 2 | 36.1K |
| Brady Kevin M.CFO & Treasurer · 8 transactions | +113.8% | 12.8K | 25.4K | — | 18.4K |
| Davenport Fred B JrDirector · 8 transactions | — | 11.3K | 18.8K | — | 15.0K |
| McCarthy Cornelius P. IIIDirector · 15 transactions | +6195.1% | 10.3K | 11.8K | — | 1.7K |
| Kraft Robert O.Director · 17 transactions | +390.4% | 922 | 15.3K | — | 14.6K |
| Keating Ashley M.Director · 9 transactions | -87.5% | 250as of May 2024 | 2.0K | — | 1.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -3.90M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.